Clinical Trials on NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Total 751 results

Allarity Therapeutics

Completed

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (LiPlaCis)

Phase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Denmark
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Cornerstone Pharmaceuticals

Completed

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Lymphoma | Metastatic Cancer | Advanced Cancer | Solid Tumors | Advanced Malignancies

United States, Canada
MapKure, LLC

Recruiting

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Colorectal Cancer | Pancreatic Ductal Cancer | Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Australia, United States
Chinook Therapeutics, Inc. (formerly Aduro)
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Advanced/Metastatic Solid Tumors or Lymphomas

United States
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
Institut Paoli-Calmettes
Société Francophone d'Onco-Gériatrie

Unknown

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies (EPITOP-01)

Advanced or Metastatic NSCLC | Advanced or Metastatic Melanoma

France
Institut Cancerologie de l'Ouest

Recruiting

Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy (IPPACTTO)

Relapsed Hematologic Malignancy | Advanced or Metastatic Solid Tumor

France
Deciphera Pharmaceuticals LLC

Completed

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Canadian Cancer Trials Group
Ottawa Hospital Research Institute

Active, not recruiting

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

Advanced/Metastatic Solid Tumours

Canada
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

United States
AlaMab Therapeutics (Shanghai) Inc.

Not yet recruiting

A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

Advanced Solid Tumors With Bone Only Metastasis
ImmuneOncia Therapeutics Inc.

Completed

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Solid Tumor | Metastasis | Locally Advanced

Korea, Republic of
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
Children's Oncology Group

Completed

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

United States, Canada
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

United States
Takeda

Completed

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Spain, Italy, Netherlands, France
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
NKGen Biotech, Inc.
Affimed GmbH

Terminated

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Metastatic Tumor | Refractory Tumor

United States
EMD Serono
Sanofi

Completed

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Italy, Spain
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Centre Leon Berard

Completed

Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors (PARASOL)

Metastatic Renal Cell Carcinoma | Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed

France
Werewolf Therapeutics, Inc.

Recruiting

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Advanced or Metastatic Solid Tumors

United States
Peking University

Recruiting

UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor

China
Eisai Inc.
Quintiles, Inc.

Terminated

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Advanced or Metastatic Solid Tumors | Previously Untreated Gastric Cancer

United States, Russian Federation, United Kingdom, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Active, not recruiting

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | BRAF NP_004324.2:p.V600X | KRAS wt Allele

United States
Phost'In Therapeutics

Recruiting

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (PhAST)

Glioblastoma Multiforme | Metastatic Cancer | Advanced Solid Tumor | Malignant Tumor

Italy, France
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Advanced Solid Tumors | Relapsed Or Refractory Non-Hodgkin Lymphoma

China
Nykode Therapeutics ASA
Nektar Therapeutics; Vaccibody AS

Completed

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer (DIRECT-01)

Locally Advanced or Metastatic Solid Tumours

Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC... and other conditions

United States
Tyligand Bioscience (Shanghai) Limited

Recruiting

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

China
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaborators

Recruiting

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C Mutation

United States
University of Southern California
National Cancer Institute (NCI); Auransa, Inc.

Recruiting

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Advanced Hepatocellular Carcinoma | Metastatic Malignant Neoplasm in the Liver | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Novartis Pharmaceuticals

Completed

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Advanced or Recurrent Solid Tumors

Japan
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
St. Jude Children's Research Hospital
Pfizer; Ipsen

Active, not recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Lymphoma | Advanced Cancer | Refractory Solid Tumors

United States
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Advanced Breast Cancer | Metastasis Solid Tumors

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Calithera Biosciences, Inc

Active, not recruiting

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | RAS Wild Type Colorectal Cancer | Refractory Colorectal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast Carcinoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Taiwan, United States, Netherlands, Spain, Korea, Republic of, Italy, Japan, Canada, Singapore
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Advanced Solid Tumors | Relapsed/Refractory Lymphoma

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China

Clinical Trials on NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations